Researchers showed the potential of combining 2 precision medicines to overcome treatment resistance. When palbociclib, a breast cancer drug, and crizotinib, a lung cancer drug, were used in ...
Investigators sought to determine whether adding gedatolisib to fulvestrant, with or without palbociclib, improved clinical outcomes in patients with HR-positive/HER2-negative/PIK3CA wild-type ...
Zacks Investment Research on MSN
Roche's giredestrant misses key goal in first-line breast cancer study
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination ...
Please provide your email address to receive an email when new articles are posted on . The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen ...
Palbociclib plus endocrine therapy did not improve overall survival in premenopausal patients with metastatic breast cancer. The regimen did improve progression-free survival compared with ...
The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients with ...
Please provide your email address to receive an email when new articles are posted on . Palbociclib plus endocrine therapy was not associated with lowered quality of life among Black, indigenous and ...
ERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free ...
NEW YORK--(BUSINESS WIRE)-- As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a ...
MUNICH -- Median survival in advanced hormone receptor-positive (HR+) improved by as much as 10 months in patients who received the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) in ...
Female patient on hospital bed. Palbociclib added to adjuvant endocrine therapy failed to improve iDFS. The following article features coverage from the 2021 San Antonio Breast Cancer Symposium. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results